| 24.28 0.53 (2.23%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.04 |
1-year : | 33.92 |
| Resists | First : | 24.87 |
Second : | 29.04 |
| Pivot price | 21.53 |
|||
| Supports | First : | 21.19 |
Second : | 18.92 |
| MAs | MA(5) : | 22.04 |
MA(20) : | 21.5 |
| MA(100) : | 18.34 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 73.3 |
D(3) : | 50.1 |
| RSI | RSI(14): 63.5 |
|||
| 52-week | High : | 26.65 | Low : | 8.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BBNX ] has closed Bollinger Bands are 14.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.9 - 25 | 25 - 25.09 |
| Low: | 23.21 - 23.32 | 23.32 - 23.43 |
| Close: | 24.1 - 24.27 | 24.27 - 24.44 |
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
Tue, 28 Oct 2025
Beta Bionics, Inc. SEC 10-Q Report - TradingView
Tue, 28 Oct 2025
Earnings Flash (BBNX) Beta Bionics, Inc. Reports Q3 Revenue $27.3M, vs. FactSet Est of $24.0M - MarketScreener
Tue, 28 Oct 2025
Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance - Yahoo Finance
Mon, 27 Oct 2025
Beta Bionics’ iLet Experience Study: A Game-Changer in Diabetes Management? - TipRanks
Mon, 27 Oct 2025
What to Expect from Beta Bionics Inc (BBNX) Q3 2025 Earnings - Yahoo Finance
Fri, 24 Oct 2025
Beta Bionics, Inc. (BBNX) Stock Analysis: Strong Buy Ratings And 26.9% Upside Potential - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Equipment & Services
|
|
| Shares Out | 43 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 106 (%) |
| Shares Short | 4,170 (K) |
| Shares Short P.Month | 3,880 (K) |
| EPS | -1.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.94 |
| Profit Margin | -94.1 % |
| Operating Margin | -85.6 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 54.4 % |
| Gross Profit (p.s.) | 0.96 |
| Sales Per Share | 1.79 |
| EBITDA (p.s.) | -1.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -14.37 |
| PEG Ratio | 0 |
| Price to Book value | 3.49 |
| Price to Sales | 13.52 |
| Price to Cash Flow | -18.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|